Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $67.50.

Several equities research analysts have weighed in on the company. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday. Canaccord Genuity Group increased their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, August 14th. HC Wainwright lifted their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Finally, B. Riley Financial restated a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th.

Eton Pharmaceuticals Stock Up 7.0%

Shares of Eton Pharmaceuticals stock opened at $59.49 on Friday. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 156.55 and a beta of 0.90. Eton Pharmaceuticals has a twelve month low of $14.27 and a twelve month high of $66.37. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. The business’s 50 day simple moving average is $53.37 and its 200-day simple moving average is $37.47.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analyst estimates of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. Equities research analysts forecast that Eton Pharmaceuticals will post 1.13 earnings per share for the current year.

Insider Activity at Eton Pharmaceuticals

In other news, insider David Krempa sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the transaction, the insider directly owned 37,025 shares in the company, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the transaction, the director directly owned 59,745 shares of the company’s stock, valued at $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 16.49% of the company’s stock.

Institutional Trading of Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at about $68,629,000. Nantahala Capital Management LLC acquired a new stake in Eton Pharmaceuticals in the second quarter worth about $42,569,426. Pillsbury Lake Capital LLC acquired a new stake in Eton Pharmaceuticals in the second quarter worth about $14,015,083. Panoramic Capital LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $7,537,000. Finally, Cannell Capital LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $6,181,041. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for underserved patient populations, with an emphasis on pediatric, rare disease and other difficult-to-treat conditions. The company generally pursues products with established clinical or regulatory pathways and works to bring them to market through its own commercial operations or strategic partnerships.

Eton’s marketed portfolio includes Eprontia, an oral solution formulation of topiramate used in the treatment of certain seizure disorders; Biorphen, an injectable phenylephrine product used to treat clinically important low blood pressure; and Alkindi Sprinkle, a hydrocortisone granule product for replacement therapy in children with adrenal insufficiency.